Research By Markets adds Market Research Report - Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H1 2020
For detailed information: https://www.researchbymarkets.com/report/type-1-diabetes-juvenile-diabetes-pipeline-review-h1-2020-605501.html
Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H1 2020
Type 1 Diabetes – Pipeline Review, H1 2020, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape.
Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.
Type 1 Diabetes – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 1 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 2, 10, 34, 28, 1, 116, 23 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 1, 1, 31 and 4 molecules, respectively.
Type 1 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Type 1 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Ahead Therapeutics SL
Akston Biosciences Corp
Algiax Pharmaceuticals GmbH
Altheia Science SRL
Amarna Therapeutics BV
APT Therapeutics Inc
Aptamer Sciences Inc
Ariddad Therapeutics SL
Artery Therapeutics Inc
Atlantic Bio Sci LLC
AVM Biotechnology LLC
Beijing Advaccine Biotechnology Company Ltd
Biozeus Pharmaceutical SA
Boston Therapeutics Inc
Bristol-Myers Squibb Co
BTB Pharma AB
Cancer Prevention Pharmaceuticals Inc
CAR-T (Shanghai) Biotechnology Co Ltd
Carlina Technologies SAS
Chongqing Chenan BioPharm Co Ltd
Cour Pharmaceuticals Development Co Inc
CRISPR Therapeutics AG
Curyx Bio Inc
Cyteir Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dendright Pty Ltd
Diabetology (Products) Ltd
Diamyd Medical AB
Diasome Pharmaceuticals Inc
Dompe Farmaceutici SpA
Eli Lilly and Co
Emerald Organic Products Inc
Ensol Biosciences Inc
Fairbanks Pharmaceuticals Inc
FasCure Therapeutics LLC
Gan & Lee Pharmaceutical Ltd
Generex Biotechnology Corp
Hanmi Pharmaceuticals Co Ltd
Housey Pharmaceutical Research Laboratories LLC
ImmunoMolecular Therapeutics LLC
Innovimmune Biotherapeutics Inc
Inversago Pharma Inc
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
Jortan Pharmaceuticals Inc
Kiniksa Pharmaceuticals Ltd
Kunming Yinnuo Medical Technology Co. Ltd.
L2 Diagnostics LLC
Landos Biopharma Inc
Lannett Co Inc
Larix Bioscience LLC
Lexicon Pharmaceuticals Inc
Maruho Co Ltd
Mercia Pharma Inc
Merck & Co Inc
Metavant Sciences Ltd
MidaSol Therapeutics LP
NextCell Pharma AB
Novo Nordisk AS
Oramed Pharmaceuticals Inc
Orion BioScience Inc
Pandion Therapeutics Inc
Paras Biopharmaceuticals Finland Oy
Parvus Therapeutics Inc
PharmaCyte Biotech Inc
PolTREG Sp z o o
Prometheon Pharma LLC
Protomer Technologies Inc
Provention Bio Inc
Purzer Pharmaceutical Co Ltd
RedHill Biopharma Ltd
Remd Biotherapeutics Inc
Renova Therapeutics Inc
Repertoire Immune Medicines
Rubius Therapeutics Inc
SAB Biotherapeutics Inc
Sahane Biotech Inc
Serpin Pharma LLC
Sihuan Pharmaceutical Holdings Group Ltd
SQZ Biotechnologies Co
Stelis Biopharma Pvt Ltd
Suntec Medical (Taiwan) Inc
Tolerx, Inc. (Inactive)
Topas Therapeutics GmbH
Transgene Biotek Ltd
Valin Technologies Ltd
Veralox Therapeutics Inc
Vertex Pharmaceuticals Inc
vTv Therapeutics Inc
XERIS Pharmaceuticals Inc
Yichang Hec Changjiang Pharmaceutical Co Ltd
Youngene Therapeutics Co Ltd
Zealand Pharma AS
Zhejiang Hisun Pharmaceutical Co Ltd
For queries regarding this report: https://www.researchbymarkets.com/sample-request/605501